Rova T Crash And Burn

Ricky tried to hide the fact in footnotes to investors that the data represent 74 percent of the trinity study population with high DLL3 expression. Investors and Street caught it easily and now Ricks looking untrustworthy. This is major news and hurts Abbvie big time.

 

Now Street/Investor sentiment shifting negative and will stay there. Humira clock ticking. Pipeline just took a MAJOR HIT.
Tick Tock Tick Tock

 

******************
While its true ABBV took a minor hit today on the market, it represents a golden opportunity for all employees - management through rank & file - to jump in at this bargain price. Expect a robust rebound and ABBV will be the talk of Wall Street !
*******************

 

Yes, I bought some ABBV today!!!!

 

This is a catastrophic event.

 

Patients in the phase 2 trial had already been selected because of DLL3 expression, since Rova-T specifically targets that protein. AbbVie’s release honed in more on patients with high DLL3 expression, and even then could only report less-than-stellar results.

 

its risky. people are taking profits. So what.

We are well positioned and funded.

 

Must also take into account the Dow dropped 724 yesterday. We'll see if Abbv rebounds.
Let's see if negative sentiment by investors continues. I say long term, it does.

 

The biggest mistake many (including me) make is panicking and selling on the dip. Smart money managers know this. That's why they do well. This company is rock-solid and believe me its actually a time to dollar cost average some more buying. I look at these dips as a sale opportunity to buy cheap.

 

Street Chatter On Abbvie ONC and Rova T by Leerink analyst Geoffrey Porges
"The investor disappointment reflects an unraveling of the company's overall solid tumor oncology strategy, as well as questions about its business development discipline and judgement, and the quality and reliability of management's long-term revenue forecasts,"

 

You.,my friend, are the quintessential Cafepharma troll. Your posts are obvious a mile away, and all garbage!

 

This is an accurate quote and those who don't like it, well TS !! Fact is Abbvie strategy, what there is, has not been adequately communicated to the financial community and that has resulted in the dip in ABBV share price. For instance the Street expects a more determined fiscal discipline strategy and a rollback of the outrageous salary and benefit structure for the sales team. For instance the 1,000 share 'gift' to non management is a real show stopper to Wall Street. That is way too generous.

 

Big loss for Abbvie's pipeline. Nothing to replace Rova T and Humira sales are flattening with biosimilars around the corner. Management has been to complacent and full of themselves.

 

With a college drop out at the helm, that's to be expected.
Abbvie will go down faster than the titanic and Linda Lovelace.

 

***************
First of all our CEO has several honorary doctorates, this being far more impressive than a ordinary PhD. He is considered one of the world leaders in bio pharma, highly regarded by his peer group of CEOs. He is also a major draw at bio conferences and a mentor to up and coming leadership. He is generous to a fault. He loves his employees like family. Please retract your evil post.
****************

 

Who is Linda Lovelace?

 

Dow UP +360 and ABBV DOWN $1.68 -- negative sentiment lingers and AbbVie is ready to crash and burn.


AbbVie Inc
NYSE: ABBV - Mar 26, 10:55
$95.81 USD DOWN -$1.68 (1.72%)

Dow Jones Industrial Average
INDEXDJX: .DJI - Mar 26 !0:55
23,899.57 UP +366.37 (1.56%)

 

Market cap down by $27 BILLION. Investors bailing out. Negative sentiment getting worse.
Clock ticking down on Humira. This is a critical matter that Richard needs to address, but he's hiding
and silent while investors take a huge hit.

ABBV
$93.20 USD Down −$4.29 (4.40%)
Mar 26, 12:43 PM

Dow
23,950.30 UP +417.10 (1.77%)
Mar 26, 12:45 PM EDT

 

Rova T is DOA
The results shown in the presentation were even worse than we had feared, and although AbbVie’s stock sold off much more than the value of Rova- T after the announcement, we can’t help but regard the ongoing trials as largely fruitless exercises. Furthermore, the toxicity signal from the trial, along with the relatively marginal efficacy signal, justifies the complete elimination of all revenue associated with Rova-T from our company forecast and valuation for AbbVie. There was a lot to dislike about the data, he says, including the high 34% discontinuation rate in the study; “49 or these 116 premature discontinuations were due to progressive disease, with the others being due to adverse events or other undisclosed reasons.”For the primary endpoint over response rate, measured by change in the target lesion, of the 301 evaluable patients (presumably the other 38 patients were deceased or lost to follow up), the investigator-measured response rate was 18%, increasing modestly to 19.7% in the DLL3 high group. As measured by the independent review board, the response rate fell to 12.4% for the combined population, and 14.3% in the DLL3-high patients. And serious adverse events in the drug group ran high. Ultimately it seems unlikely in our view that Rova-T, or perhaps any variant of DLL3 antibody-drug conjugate medicine, will come to market, at least while the profile looks the way it did in TRINITY.
Porges conclusion: The drug and the class look dead on arrival at ASCO.

 

The above says it all..Rova T is DOA and put a fork in it. Next ABBV is headed into toiletland. Recommend immediate sell off of some of holdings. The fat lady is going to sing very soon !!